Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: A study of bortezomib and thalidomide [7]

Leukemia

Volumn 21, Issue 4, 2007, Pages 818-820

  Prince, H Miles ^a   Schenkel, B ^b   Mileshkin, L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; M PROTEIN; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; FOLLOW UP; HUMAN; LETTER; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 33947383374     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404573     Document Type: Letter

References (8)

1. Durie BG, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al., for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
2. Chronic Leukemia and Myeloma Task Force of the National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145-158.
3. Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382-389.
4. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, for the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
5. Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48: 46-55.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316-1319.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al., for the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.